Sign in →

Epic Code LAB155 CA 125 Level

Important Note

Testing performed by Roche Cobas systems by Electrochemiluminescence Immunoassay.  Serum markers are not specific for malignancy. Assays using different manufacturers for methods may not be comparable.

Test Name Alias

Cancer Antigen 125 Level | CA 125 Level | Ovarian Cancer-Related Antibodies | CA125 | 6786

Interface Order Alias

10025

Collection Instructions

Specimen Collection: Blood

 

Container(s): 4.5 mL Mint Green Top (Lithium Heparin Gel) or 5.0 mL Gold Top (Serum Separator-SST Gel)

Preferred Volume to Collect: 4.5 mL

Minimum Volume to Collect: 2.0 mL

Neonate Volume to Collect: 1.0 mL

Capillary collect ok? Yes

Microtainer acceptable: Yes

 

Collection Instructions:

  • After collection, gently invert tube 8-10 times.
  • Specimen should be processed within 2 hours – See Processing Instructions.

Processing Instructions (Laboratory, Outpatient or Off-site collection)

  • Processed Specimen: Plasma or Serum
  • Centrifuge/Spin: Yes
  • Aliquot: Yes
  • Processing Instructions:
    • Plasma is preferred specimen type
    • Green Tube/Plasma: Centrifuge after collection.
    • Gold Tube/Serum: Allow blood to clot for 30 minutes in a vertical position and centrifuge within 2 hours.
    • Minimum volume: 1.0 mL plasma or serum
  • Transport Temperature: Refrigerated

Specimen Stability

Ambient: 8 hours

Refrigerate: 72 hours

Frozen: aliquot plasma/serum for longer storage

Laboratory Retention: 72 hours

Test Frequency

Available daily, usual TAT 1 day

Reference Range

≤ 38.0 U/mL

Performing Department

Chemistry

Performing Department Laboratory Location

Corewell Health Reference Laboratory, Grand Rapids, MI

Methodology

Method is Roche cobas Electrochemiluminescense Immunoassay.
Patient results determined by assays using different manufacturers for methods may not be comparable.

CPT

86304

CDM Code

3028630401

Epic Test ID

1230100433

LOINC

CA 125 : 10334-1

Mayo Access Code

SHO6786

Reviewed Date

3/7/2024

Updated Date

3/14/2024 - Reference Range and Important Note